GHRS
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GH Research PLC (GHRS) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D- (1.1) | C- (2.1) | C (2.3) | C+ (2.6) | C- (2.1) |
| 2026-11-05 | C+ (2.5) | D- (1.1) | C- (2.0) | C (2.4) | C+ (2.7) | C- (2.1) |
| 2026-10-29 | C+ (2.5) | D- (1.1) | C- (2.0) | B- (3.0) | C+ (2.7) | C (2.2) |
| 2026-10-22 | C+ (2.5) | D- (1.1) | C- (2.0) | B- (3.1) | C+ (2.6) | C (2.3) |
| 2026-10-15 | C+ (2.5) | D- (1.1) | C- (2.0) | B (3.2) | C+ (2.6) | C (2.3) |